HeartBeam, Inc. reported its financial results for the first quarter of 2026, revealing a net loss of $4.7 million, a decrease from the $5.5 million loss recorded in the same period of 2025. The company's total operating expenses for the quarter were $4.7 million, down 14% from $5.5 million year-over-year. This reduction was primarily driven by a significant decrease in research and development expenses, which fell by 32% to $2.4 million, compared to $3.5 million in the prior year. Selling, general, and administrative expenses increased by 17% to $2.3 million, largely due to non-cash stock-based compensation.
As of March 31, 2026, HeartBeam's cash and cash equivalents stood at approximately $2.0 million, a decline from $4.4 million at the end of 2025. The company has indicated that its existing liquidity is insufficient to fund operations for the next twelve months, raising concerns about its ability to continue as a going concern. In response to this financial situation, HeartBeam successfully raised $11.5 million in gross proceeds from an underwritten offering that closed in April 2026, which is expected to support its ongoing operations and strategic initiatives.
Operationally, HeartBeam has made significant strides in its product development and market strategy. The company has initiated a limited commercial launch of its HeartBeam System, which received FDA clearance for arrhythmia assessment in December 2024. The first commercial customer, ClearCardio, was announced in March 2026, marking the beginning of a staged rollout to validate the product's performance. Additionally, HeartBeam is pursuing an expansion of its product offerings, including a novel on-demand 12-lead ECG patch, with a pilot study currently underway in Serbia.
The company has also expanded its geographic footprint through partnerships with concierge medical practices, including Atelier Health, which will enhance its presence in key markets such as New York, Dallas, South Florida, and Southern California. As of March 31, 2026, HeartBeam employed 17 individuals, including a newly appointed Chief Commercial Officer, who will lead the commercialization strategy for the HeartBeam System and other growth initiatives.
Looking ahead, HeartBeam aims to leverage its recent funding to advance its product development and commercialization efforts. The company is focused on achieving critical clinical and regulatory milestones while exploring additional capital-raising opportunities to ensure its long-term viability. Despite the challenges posed by market conditions and competition, HeartBeam remains committed to transforming cardiac care through innovative technology and personalized insights.
About HeartBeam, Inc.
HeartBeam, Inc. develops portable, FDA-cleared cardiac monitoring devices utilizing proprietary technology to capture high-fidelity ECG signals from three directions. Its products enable remote detection and diagnosis of cardiac conditions, including arrhythmias and heart attacks, through user-friendly, cable-free hardware and cloud-based software. Targeting healthcare providers and patients, the company aims to improve early diagnosis, reduce healthcare costs, and expand advanced cardiac diagnostics outside clinical settings.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.